Related Experiment Video

Updated: Jan 29, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

28.7K

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer

Maria Bonello1, Andrew Harvey Sims1, Simon Peter Langdon1

  • 1Cancer Research UK Edinburgh Center and Division of Pathology Laboratory, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.

Cancer Biology & Medicine
|February 16, 2019
PubMed

Insights

Targeting human epidermal growth factor receptors (EGFR, ERBB2) with new drugs offers hope for ovarian cancer patients who relapse. These therapies, including monoclonal antibodies and tyrosine kinase inhibitors, are being studied for resistant disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Ovarian cancer is a leading cause of cancer death globally.
  • Most patients initially respond to treatment but often develop resistant disease, necessitating novel therapeutic strategies.
  • The human epidermal growth factor receptor (HER) family, including EGFR and ERBB2, plays a role in ovarian cancer progression.

Purpose of the Study:

  • To review the human epidermal growth factor receptor family in the context of ovarian cancer.
  • To examine emerging clinical studies on targeted therapies for ovarian cancer.
  • To propose future research directions for HER-targeted treatments in ovarian cancer.

Main Methods:

  • Literature review of the human epidermal growth factor receptor family.
  • Analysis of emerging clinical studies on monoclonal antibodies and tyrosine kinase inhibitors in ovarian cancer.
  • Synthesis of current research to identify future therapeutic possibilities.

Main Results:

  • Human epidermal growth factor receptors are implicated in ovarian cancer progression and resistance.
  • Monoclonal antibodies and tyrosine kinase inhibitors targeting HER receptors show potential in various cancers.
  • Clinical studies are exploring the efficacy of these targeted agents in ovarian cancer, particularly in resistant cases.

Conclusions:

  • Targeting the human epidermal growth factor receptor family presents a promising avenue for treating ovarian cancer, especially in patients with resistant disease.
  • Further clinical investigation of monoclonal antibodies and tyrosine kinase inhibitors is warranted.
  • Future research should focus on optimizing these targeted therapies for improved patient outcomes in ovarian cancer.
Keywords:
HERTyrosine kinaseinhibitorsmonoclonal antibodiesovarian cancerreceptors

More Related Videos

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

8.7K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
518
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.8K
Factors Influencing Microbial Growth: pH01:29

Factors Influencing Microbial Growth: pH

Microorganisms are classified as acidophiles, neutrophiles, or alkaliphiles based on their pH growth preferences, reflecting their adaptations to specific environments. Maintaining a stable intracellular pH is critical for macromolecular stability and enzymatic activity, which can be challenged by external pH variations.Neutrophiles, such as Escherichia coli, grow optimally between pH 5.5 and 8.0. These microorganisms inhabit neutral or slightly acidic environments and employ mechanisms like...
1.1K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
595
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K